<DOC>
	<DOCNO>NCT00005946</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . White blood cell donor may able prevent graft-versus-host disease patient hematologic cancer relapse follow donor peripheral stem cell transplantation . PURPOSE : Phase I trial study effectiveness chemotherapy plus donor white blood cell infusion treat patient relapse hematologic cancer follow donor peripheral stem cell transplantation .</brief_summary>
	<brief_title>Chemotherapy Plus Donor White Blood Cell Infusion Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : I . Determine minimum amount chemotherapy combination donor lymphocyte infusion require obtain rate 30-60 % graft versus host disease patient hematologic malignancy relapse allogeneic stem cell transplantation . OUTLINE : This dose de-escalation study . Patients receive etoposide IV continuously day 1-3 ; cyclophosphamide IV day 8 ; donor lymphocyte infusion IV day 10 ; filgrastim ( G-CSF ) subcutaneously IV begin day 10 continue blood count recover . Cohorts 3-6 patient receive six de-escalating level chemotherapy minimum amount chemotherapy combination donor lymphocyte infusion require obtain rate 30-60 % graft versus host disease ( GVHD ) determine . The target dose level define level 2 6 patient develop GVHD , next low dose level 1 patient experience GVHD . Patients follow every 3 month first year , every 6 month second year , yearly thereafter . PROJECTED ACCRUAL : A total 18-21 patient accrue 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm relapsed refractory hematologic malignancy Acute leukemia Myelodysplasia NonHodgkin 's lymphoma Hodgkin 's disease Multiple myeloma Chronic lymphocytic leukemia Chronic myeloid leukemia Accelerated phase blast crisis Chronic phase fail prior donor lymphocyte infusion No active acute extensive chronic graft versus host disease Prior allogeneic stem cell transplant ( SCT ) require At least 60 day since prior SCT Nonmyeloablative SCT allow PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : Greater 4 week Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No severe psychiatric illness may preclude informed consent Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 7 day since prior immunomodulatory medication ( e.g. , interferon interleukin2 ) Chemotherapy : Not specify Endocrine therapy : At least 7 day since prior steroid Radiotherapy : Not specify Surgery : Not specify Other : At least 7 day since prior immunosuppressive ( e.g. , cyclosporine , tacrolimus , mycophenolate mofetil ) No concurrent immunosuppressive medication graft versus host disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>